aTyr Pharma Advances Efzofitimod to New Phase 3 in Pulmonary Sarcoidosis After FDA Feedback

What happened

After the EFZO-FIT Phase 3 primary endpoint miss, aTyr Pharma held a Type C meeting with the FDA and has now announced plans to submit a new IND in June 2026 for a confirmatory Phase 3 study in chronic symptomatic pulmonary sarcoidosis with restrictive lung disease. The new study will use forced vital capacity (FVC) as the primary endpoint and KSQ-Lung as a key secondary endpoint, reflecting FDA input. This regulatory path is narrower than the prior failed study and suggests the agency accepted a more focused endpoint strategy, consistent with the bullish scenario outlined in the DeepValue report where FDA minutes specify an approvable endpoint strategy. However, the company still faces Nasdaq minimum-bid compliance by June 2, 2026, and the new trial will require additional capital, raising dilution risk given the current sub-$1 share price. The announcement de-risks the regulatory salvage effort but confirms that a large Phase 3 is needed, which extends timeline and financing uncertainty.

Implication

The FDA Type C meeting outcome has crystallized a confirmatory path for efzofitimod, utilizing FVC and KSQ-Lung endpoints—a favorable resolution relative to a de novo large trial. This supports the DeepValue bullish scenario (20% probability) and implies the company can move forward without a complete pipeline reset. However, funding the new Phase 3 will require additional capital, likely via an ATM or partnership, and the Nasdaq listing deadline remains a near-term overhang. The stock's EV near zero still discounts considerable downside, and while the regulatory path is clearer, execution and financing risks persist. Investors should monitor the IND submission and any capital raise terms.

Thesis delta

The thesis shifts from a binary FDA salvage gamble to a defined confirmatory program with clearer endpoints but heightened financing needs. The bear-case probability (35%) has decreased as the FDA did not demand an EFZO-FIT-sized redo; the base-case (45%) now likely dominates. The bull-case probability (20%) has increased with the bounded plan, but dilution risk tempers upside.